Uganda
Show data as of
'Most recent data' shows most recent policy adoption levels and other data. Choosing a year shows data available for that year only.
Uganda
Show data as of
'Most recent data' shows most recent policy adoption levels and other data. Choosing a year shows data available for that year only.
Overall country policy adoptionOverall policy adoption scaleCalculated for each country based on the percent of policies for which data are available that have have a score of “adopted”VERY FEW0-19% of policies have been adoptedFEW20-39% of policies SOME40-59% MANY60-79%MOST80%+
Overall policy adoption scale
Calculated for each country based on the percent of policies for which data are available that have have a score of “adopted”
VERY FEW
0-19% of policies have been adopted
FEW
20-39% of policies
SOME
40-59%
MANY
60-79%
MOST
80%+
VERY FEW
FEW
SOME
MANY
MOST
policies adopted
Policy adoption
(out of 33)
18
Adopted
7
Partial
8
Not adopted
0
Data not available
HIV incidence
52.00k
new HIV infections
in 2022
in 2022
15%
since 2017
ART treatment
84%
of people with HIV on ART in 2022
increase
from 73%
in 2017
in 2017
Meets targets for 90/90/90 goals
Policy adoption by category
VERY FEW
MOST
Overall
VERY FEW
MOST
global average
regional average
Clinical and treatment
VERY FEW
MOST
Testing and prevention
VERY FEW
MOST
Structural
VERY FEW
MOST
Health systems
VERY FEW
MOST
Policy adoption by question
Clinical and treatment
Contact Us
CT
MOST
Category / topic
Question
Adoption level
Not
adopted
adopted
Partially
adopted
adopted
Adopted
CT1
Treatment initiation
Are all people living with HIV, regardless of CD4 count, eligible to start HIV treatment in national policy?
CT2
Same-day treatment start
Is the option to start treatment the same day as HIV diagnosis included in national policy?
CT3
Treatment regimen
Are up-to-date first-line ARV regimens aligned with international recommendations included in national HIV policy?
CT4
Differentiated service delivery (3‑part)
Do national HIV treatment policies include multiple options for differentiated HIV treatment services?
i
Does national policy allow for community ART distribution?
ii
Does national policy allow for reduced frequency of clinical visits?
iii
Does national policy allow for multi-month dispensing?
CT5
Viral load testing
Is viral load monitoring at least once per year provided for in national policy?
CT6
Pediatric diagnosis & treatment (2‑part)
Are national pediatric testing and treatment policies aligned with international recommendations?
i
Does early infant diagnosis policy align with WHO recommendations on the use of point-of-care tests?
ii
Does the first-line ARV regimen for infants and children included in national guidelines align with WHO recommendations?
CT7
Migrants access to healthcare (2‑part)
Are HIV services and primary healthcare available to all migrants under the same conditions as citizens under national policy?
i
Is primary healthcare available to all migrants under the same conditions as citizens under national policy?
ii
Are HIV services available to all migrants under the same conditions as citizens under national policy?
CT8
TB diagnostics
Are rapid diagnostic tests (e.g. rapid molecular diagnostics, TB-LAM) aligned with WHO recommendations used as the initial diagnostic test for TB in PLHIV under national policy?
Testing and prevention
Contact Us
TP
MANY
Category / topic
Question
Adoption level
Not
adopted
adopted
Partially
adopted
adopted
Adopted
TP1
Self-testing
Is self-testing approved in national policy?
TP2
Partner notification/Index testing (2‑part)
Is index testing/partner notification, with robust protections for patient confidentiality, provided for in national policy?
i
Is index testing/partner notification provided for in national guidelines?
ii
Do partner notification guidelines include confidentiality and robust protections against disclosure of HIV status without patients consent?
TP3
Compulsory testing
Is compulsory HIV testing prohibited under national law?
TP4
Age restrictions on testing & treatment
Can adolescents access HIV testing and treatment without parental consent under national policy?
TP5
PrEP (2‑part)
Are all people/populations at substantial risk of HIV infection eligible for PrEP under national policy and have technologies for pre-exposure prophylaxis (PrEP) received national regulatory approval?
i
Are people/populations at substantial risk of HIV infection identified and eligible for PrEP under national policy?
ii
Has at least one form of PrEP received national regulatory approval?
TP6
Harm reduction (2‑part)
Does national law and HIV policy incorporate key harm reduction strategies, including avoidance of criminalizing syringe possession?
i
Is harm reduction included in national policy & service packages for people who inject drugs?
ii
Does national law avoid imposing criminal penalties for possession of syringes and associated paraphernalia?
TP7
Comprehensive sexuality education
Is comprehensive sexuality education required in primary and secondary schools under national policy?
TP8
Prisoners prevention (2‑part)
Are both condoms/lubricants and syringe access/exchange programs available to prisoners as a matter of policy?
i
Are condoms/lubricant available in prisons as a matter of national policy?
ii
Are syringe access/exchange programs available in prisons as a matter of national policy?
S1
Same-sex sex non-criminalization (2‑part)
Does national law/policy refrain from criminalizing and prosecuting people for consensual same-sex sexual acts?
i
Does national law refrain from criminalizing consensual same-sex sexual acts?
ii
Has law-enforcement policy avoided prosecution for consensual same-sex acts in recent years?
S2
Sex work non-criminalization
Does national law avoid criminalizing sex work (buying, selling, and organizing of sex work)?
S3
Drug use non-criminalization
Does national law refrain from criminalizing personal drug use/possession?
S4
HIV exposure non-criminalization (2‑part)
Does national law refrain from criminalizing and prosecuting people for HIV exposure/ transmission?
i
Does national law refrain from criminalizing HIV exposure/transmission?
ii
Has law-enforcement policy avoided arrests/prosecution for HIV transmission/exposure in recent years?
S5
Non-discrimination protections (3‑part)
Do national laws/policies include protections from discrimination on the basis of sexual orientation, gender identity, and HIV status?
i
Do national laws protect people from discrimination on the basis of sexual orientation?
ii
Do national laws protect people from discrimination on the basis of gender identity/diversity?
iii
Do national laws protect people from discrimination on the basis of HIV status?
S6
National human rights institutions
Is there an independent national human rights institution to which violations can be reported?
S7
Constitutional right to health
Is there an enforceable right to health in the national constitution?
S8
Girls education
Is there a national policy in place to encourage secondary school retention among girls?
S9
Gender based violence
Does the law explicitly address domestic violence with enforceable penalties?
S10
Civil society (2‑part)
Are NGOs/CSOs able to register, seek funding and operate freely under national law and is there a social contracting policy for financing NGOs/CSO-provided services?
i
Does national policy provide for social contracting (or other mechanisms by which the government finances CSOs to provide health services)?
ii
Are NGOs/CSOs, including those working with key populations, able to officially register, seek funding, and operate freely under national laws and policies?
Health systems
Contact Us
HS
MANY
Category / topic
Question
Adoption level
Not
adopted
adopted
Partially
adopted
adopted
Adopted
HS1
Task shifting
Are nurses or other non-physicians allowed to initiate HIV treatment under national policy?
HS2
Health financing (2‑part)
Does the national budget and fiscal policy include sufficient health spending and adequate tax revenues to meet international targets?
i
Does the percent of government spending going to health align with the Global Fund co-financing targets?
ii
Does government collect adequate tax revenue to align with the tax:GDP ratio in the Global Fund co-financing targets?
HS3
Universal health coverage (2‑part)
Does national health coverage include medications for HIV treatment & pre-exposure prophylaxis (PrEP)?
i
Are ARVs covered by the national health system/scheme?
ii
Is PrEP covered by the national health system/scheme?
HS4
User fees (2‑part)
Are public primary healthcare and HIV services available without user fees at the point of service under national policy?
i
Are primary healthcare services in public facilities available without user fees?
ii
Are HIV services in public facilities available without user fees?
HS5
Access to medicines (TRIPS) (2‑part)
Does national law/policy take advantage of TRIPS flexibilities for affordable medicines?
i
Are TRIPS flexibilities (including parallel importation, compulsory licensing, and LDC extension) incorporated in national law?
ii
Are there documented examples of the country utilizing TRIPS flexibilities?
HS6
Unique identifiers with data protections (2‑part)
Are unique identifiers for continuity of care across multiple facilities included in national policy along with protections for patients' privacy?
i
Is there a unique ID (or other method of de-duplicating data) that allows for continuity of care across multiple facilities?
ii
Does national law include legally enforceable protections against disclosure of individually-identifiable health data, including HIV status?
HS7
Data sharing (2‑part)
Is it national policy to publicly share disaggregated HIV data on a regular basis?
i
Is data disaggregated by geographic region, age, and gender?
ii
Is data shared at least quarterly?